Forum: Koffiekamer » Intellia Therapeutics 2024 » Pagina: 9

Rick96 16 april 2024 15:48

Nog geen beste keuze geweest..

Hoger Lager 17 april 2024 16:56

quote:
Rick96 schreef op 16 april 2024 15:48:
Nog geen beste keuze geweest..

Door de oorlog zijn de meeste koersen gedaald. Ik zit LT

Hoger Lager 29 april 2024 17:08

Intellia Therapeutics, Inc.
April 29, 2024 7:30 AM EDT
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up
Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).

Presentation Details

Title: CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study

Session: Breakthroughs in management of Hereditary Angioedema

Date and Time: Sunday, June 2, 2024, from 8:30 – 10:00 a.m. CET

Presenter: Hilary Longhurst, M.D., Ph.D., FRCP, FRCPath, Senior Medical Officer at Auckland District Health Board and Honorary Associate Professor at University of Auckland, New Zealand, the trial’s principal investigator in New Zealand

Hoger Lager 30 april 2024 19:45

HAE arts en HAE patiënt over genezing van HAE (resultaten clinical trial van Intellia ntla-2002, phase 1/2)
www.rarediseaseadvisor.com/features/g...

AEX	878,83	-0,39%
EUR/USD	1,0655	-0,13%
FTSE 100	8.144,13	0,00%
Germany40^	17.905,20	-1,18%
Gold spot	2.287,52	-2,07%
NY-Nasdaq Composite	15.657,82	-2,04%

Care P...	+0,52 +3,87% 0.52 3.8748
Xior	+0,45 +1,63% 0.45 1.6334
SHURGARD	+0,45 +1,18% 0.45 1.1827
KBC Groep	+0,62 +0,89% 0.62 0.8949
EVS	+0,30 +0,89% 0.3 0.8915

IBA	-0,42 -3,23% -0.42 -3.2308
Melexis	-2,15 -2,66% -2.15 -2.656
TINC	-0,32 -2,61% -0.32 -2.6144
AZELIS...	-0,52 -2,25% -0.52 -2.2453
Aedifica	-1,35 -2,20% -1.35 -2.1951

Beurscodes, betekenis en hulp bij zoeken

Europa

Noord-Amerika

Kunt u een instrument niet vinden?

Waar vind ik die ISIN code?

Inloggen

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Krijg toegang tot vele voordelen

Profiteer van de IEX producten

Nederland

Europa

Amerika

Koffiekamer« Terug naar discussie overzicht

Intellia Therapeutics 2024

Rick96

Aanbevelingen

Aantal posts: 61

Hoger Lager

Aanbevelingen

Aantal posts: 282

Hoger Lager

Aanbevelingen

Aantal posts: 282

Hoger Lager

Aanbevelingen

Aantal posts: 282

Meedoen aan de discussie?

Direct naar Forum

Indices

Stijgers

Dalers

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Bitvavo

Nederlandse MKB Participatiemaatschappij

Hét Warren Buffett-pakket al aangevraagd?

Pearl Capital: beleggen met zekerheid

Meld u aan voor de dagelijkse Beursupdate

Verzoek